Tonix Pharmaceuticals Holding (TNXP) FCF Margin (2022 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly FCF Margin came in at 639.87% in Q1 2026, up 4293.0% year-on-year from 14.57% in Q1 2025, and up 16.94% quarter-over-quarter from 770.39% in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) FCF Margin (2022 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's FCF Margin history runs 5 years deep, the most recent figure standing at 639.87% for Q1 2026.
- On a quarterly basis, FCF Margin rose 4293.0% year-over-year to 639.87% in Q1 2026; TTM through Mar 2026 was 744.12%, a 14710.0% decrease from a year earlier, with the FY2025 full-year figure at 787.46%, down 18270.0% from the prior year.
- FCF Margin grew to 639.87% in Q1 2026 per TNXP's latest filing, from 770.39% in the prior quarter.
- Across five years, FCF Margin topped out at 449.23% in Q2 2024 and bottomed at 904.29% in Q3 2025.
- The 5-year median for FCF Margin is 697.62% (2024), against an average of 702.97%.
- Across the five-year window, FCF Margin jumped 32615 bps in 2023 and plunged 31919 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 890.1% in 2022, then increased by 11 bps to 792.8% in 2023, then increased by 29 bps to 566.73% in 2024, then sank by 36 bps to 770.39% in 2025, then climbed by 17 bps to 639.87% in 2026.
- Per Business Quant, the three latest TNXP FCF Margin figures stand at 639.87% (Q1 2026), 770.39% (Q4 2025), and 904.29% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn | -639.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -639.87% |
| Dec 31, 2025 | -770.39% |
| Sep 30, 2025 | -904.29% |
| Jun 30, 2025 | -768.42% |
| Mar 31, 2025 | -682.79% |
| Dec 31, 2024 | -566.73% |
| Sep 30, 2024 | -666.55% |
| Jun 30, 2024 | -449.23% |
| Mar 31, 2024 | -712.45% |
| Dec 31, 2023 | -792.80% |
| Sep 30, 2023 | -563.95% |
| Jun 30, 2023 | -681.94% |
| Sep 30, 2022 | -890.10% |
| Jun 30, 2022 | -752.06% |